Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy

Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer

(2021) Ming Lei et al.   CLINICAL CANCER RESEARCH

PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy

(2021) Soomin Ahn et al.   MODERN PATHOLOGY

Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19

(2021) Chun Chau Lawrence Cheung et al.   GUT

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

(2021) Jong-Mu Sun et al.   LANCET

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

(2021) Yelena Y Janjigian et al.   LANCET

Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma

(2021) Joseph J. Zhao et al.   JOURNAL OF CLINICAL ONCOLOGY

Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC

(2020) Joe Yeong et al.   JOURNAL OF CLINICAL PATHOLOGY

The Society for Immunotherapy in Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation

(2020) Janis M Taube et al.   Journal for ImmunoTherapy of Cancer

Improving the Diagnostic Accuracy of the PD-L1 Test with Image Analysis and Multiplex Hybridization

(2020) Matthew P. Humphries et al.   Cancers

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

(2020) Kohei Shitara et al.   JAMA Oncology

Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination

(2020) Raghav Sundar et al.   GUT

KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer

(2019) Ken Kato et al.   Future Oncology

PD-L1 expression in gastroesophageal dysplastic lesions

(2019) Matteo Fassan et al.   VIRCHOWS ARCHIV

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

(2018) Kohei Shitara et al.   LANCET

An automated staining protocol for seven-colour immunofluorescence of human tissue sections for diagnostic and prognostic use

(2018) Jeffrey Chun Tatt Lim et al.   PATHOLOGY

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer

(2018) Charles S. Fuchs et al.   JAMA Oncology

Tissue microarrays – translational biomarker research in the fast lane

(2018) Felix Behling et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1

(2018) Lola Fashoyin‐Aje et al.   ONCOLOGIST

PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability

(2017) Hans Brunnström et al.   MODERN PATHOLOGY

A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer

(2017) David L. Rimm et al.   JAMA Oncology

cellXpress: a fast and user-friendly software platform for profiling cellular phenotypes

(2013) Danai Laksameethanasan et al.   BMC BIOINFORMATICS